Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results

Key Points

• Perspective Therapeutics beat earnings expectations, reporting a quarterly loss of $0.22 per share versus the analyst consensus loss of $0.27. Revenue was $0.08 million, slightly below the $0.09 million estimate.
• CATX shares remained flat at $3.00, with the stock trading between a 52-week low of $1.96 and high of $6.16. Institutional investors own approximately 54.66% of the company.
• Analysts remain broadly bullish: all eight covering analysts rate the stock a Buy, with a consensus price target of $12.62, while the company advances its precision-targeted cancer therapies through Phase 1/2a trials.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05, FiscalAI reports. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX remained flat at $3.00 during trading hours on Monday. The company had a trading volume of 911,985 shares, compared to its average volume of 2,355,088. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The company has a 50-day simple moving average of $3.11 and a two-hundred day simple moving average of $3.93.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CATX. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $28,000. Russell Investments Group Ltd. boosted its holdings in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the fourth quarter valued at approximately $31,000. Engineers Gate Manager LP purchased a new position in Perspective Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $42,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Analyst Ratings Changes

CATX has been the topic of a number of recent research reports. Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $12.62.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source